MANCHESTER, England, April 20, 2021 /PRNewswire/ -- Phagenesis Ltd, a private healthcare company offering an innovative treatment for dysphagia, announces successful treatment of intubation–induced ...
Inclusion in new Acute Ischemic Stroke guidelines underscores clinical utility of Phagenyx for accelerating recovery from swallowing difficulties (dysphagia) in stroke patients NASHVILLE, Tenn., Jan.
Hosted on MSN
Pharyngeal electrical stimulation highlighted as important therapy for post-stroke dysphagia
The American Stroke Association (ASA) has formally recognised pharyngeal electrical stimulation (PES) as an important tool for post-stroke dysphagia (difficulty swallowing) treatment. In ASA’s 2026 ...
ABU DHABI, UAE — A device characterized by the US Food and Drug Administration as safe for the treatment of dysphagia following acute stroke is finally being tested for efficacy in a randomized ...
MANCHESTER, England, Nov. 11, 2020 /PRNewswire/ -- Phagenesis Ltd, a leading innovator in the treatment of dysphagia, is pleased to announce today the publication of the largest and most complex study ...
Strong supportive evidence of effectiveness is not available for many dysphagia treatments so clinicians need to use best available evidence to support therapy choice Unlike compensatory strategies, ...
The MarketWatch News Department was not involved in the creation of this content. Inclusion in new Acute Ischemic Stroke guidelines underscores clinical utility of Phagenyx for accelerating recovery ...
Inclusion in new Acute Ischemic Stroke guidelines underscores clinical utility of Phagenyx for accelerating recovery from swallowing difficulties (dysphagia) in stroke patients As the only ...
Inclusion in new Acute Ischemic Stroke guidelines underscores clinical utility of Phagenyx for accelerating recovery from swallowing difficulties (dysphagia) in stroke patients NASHVILLE, Tenn., Jan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results